pharmaphorum

JUNE 20, 2022

The rumour was first published in the Wall Street Journal, which suggests that a takeover is just one option on the table, along with a marketing deal that would bind the two companies together without the risk of antitrust issues holding up or blocking a merger. It says Merck has hesitation about whether a deal could make it through FTC.

105

105

pharmaphorum

OCTOBER 12, 2021

Sales were $20 million and $0.5 Gocovri could see its sales momentum rise following its approval for a second indication by the FDA earlier this year. per share subject to Gocovri meeting sales targets. per share subject to Gocovri meeting sales targets. million, respectively, in the second quarter of this year.

FDA 97

FDA 97

STAT

DECEMBER 22, 2023

For Bristol, the deal represents a re-entry into the market for drugs to treat psychiatric and neurological diseases. Drugmakers are slow-walking products to market to get around a federal law to lower medication prices, Bloomberg News explains. Enjoy, and see you on Jan. 2 when we return with our daily menu of tidbits.

104

104

pharmaphorum

MARCH 3, 2022

DarioHealth has beefed up its sales and marketing channels as well as its range of digital health products thanks to a $30 million strategic alliance with drugmaker Sanofi. Erez Raphael.

91

91

pharmaphorum

JUNE 1, 2022

GlaxoSmithKline is due to complete the split from its consumer health decision – now renamed Haleon – next month, with a listing for the new company on the London Stock Exchange set for 18 July. A listing on the New York Stock Exchange will follow shortly, according to the pharma group.

Vaccines 105

Vaccines 105

PharmaShots

JUNE 19, 2023

Shots: Biomm to get an exclusive right to distribute & market BAT2206 in Brazil & will be responsible for filing the dossier in Brazil. Your go-to media platform for customized news ranging for multiple indications. BAT2206 was approved in Brazil for active PsA in adults as monotx.

40

40

STAT

FEBRUARY 1, 2024

On 2024 guidance, Merck said it expects sales in the range of $62.7-$64.2 On Wall Street, that spells bad news for the riskier segments of the market, which includes biotech, and thus the XBI dipped about 2%. The company had previously forecast $1 billion in 2023 sales before cutting that number in half.

Vaccines 121

Vaccines Communication Insurance 121

PharmaShots

JUNE 5, 2023

a right of 1st negotiation for new indications of NRX-101 & new products containing D-cycloserine + antidepressant/antipsychotic Ref: Nrxpharma | Image: Alvogen PharmaShots! Your go-to media platform for customized news ranging for multiple indications. The agreement incl. The agreement incl.

FDA 40

FDA 40

pharmaphorum

MARCH 15, 2022

In return, it will get a royalty on sales if the new version gets approved. That may not prove to be a good investment, given the news this week that bempeg failed a phase 3 trial in melanoma as a combination therapy with Bristol-Myers Squibb’s Opdivo (nivolumab).

97

97

PharmaShots

MAY 26, 2023

Shots: Akebia will receive $10M up front, ~$100M in commercial milestones for rights to Vafseo in the EU & Australia along with royalty up to 30% of net sales. Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

40

40

European Pharmaceutical Review

FEBRUARY 3, 2023

The CDMO’s nine facilities use cGMP -compliant technologies, including the new site for producing sterile injectable drug products. The HPAPI market A 2022 market report showed that due to the small volumes required for dosage, small-scale providers are also gaining importance.

Dosage 96

Dosage Compounding Pharmaceutical Companies Pharmaceutical Companies 96

PharmaShots

APRIL 25, 2023

anniversary of closing, ~$450M in additional sales-based milestones, based on annual sales of $175M & $200M and total net sales over 5yr. Shots: Lilly will receive $500M in cash at closing, ~$125M upon 1yr. Baqsimi is the first nasally administered glucagon for sev.

FDA 40

FDA 40

pharmaphorum

NOVEMBER 2, 2022

GSK now expects sales to grow between 8% and 10% at constant exchange rates this year, up from its previous prediction of 6% to 8%, with an operating profit of 15%-17% versus 13%-15%. billion (around $8.9 billion) against consensus forecasts of around £7.3 Operating profit was up 18% to £2.6 May decision on RSV vaccine.

Vaccines 98

Vaccines FDA 98

European Pharmaceutical Review

JANUARY 25, 2023

To control dissemination of contaminated medicines, the World Health Organization calls on: Regulators to: Detect and remove from circulation in their respective markets any substandard medical products identified in the WHO medical alerts as potential causes of deaths and disease. NEWS: What can we learn from contamination control failures?

96

96

PharmaShots

MAY 5, 2023

Shots: Kinoxis will receive an up front & research support, ~$181M in milestones along with royalties on future Boehringer Ingelheim product sales. Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Compounding 40

Compounding 40

pharmaphorum

OCTOBER 20, 2020

Huge demand for ventilators and patient monitors spurred third quarter sales for Royal Philips, the company announced. The Dutch health technology group reported sales of €4.98bn, a 10% year-over-year growth. Sales were down 3%, to €1.97bn compared to a 9% dip in Q2.

Hospitals 105

Hospitals 105

PharmaShots

APRIL 26, 2023

Spectrum’s combined assets & commercial infrastructure will accelerate Rolvedon’s launch for patients' benefit & drive further growth The combination of Assertio’s Omni-Channel digital sales capabilities & Rolvedon's in-person commercial team will enhance market access & growth across all products Ref: Globenewswire (..)

56

56

PharmaShots

MAY 8, 2023

in sales milestones, and a fixed fee for each carton of Inbrija supplied to Chance. Your go-to media platform for customized news ranging for multiple indications. Shots: Acorda will receive $2.5M up front, ~$6M in near-term milestones, $3M upon regulatory approval, ~$132.5M

40

40

Pharma Marketing Network

JULY 13, 2023

When it comes to marketing your pharma business on Facebook, you may be wondering whether you should boost a post or create an ad. Placement: Your boosted post can appear in the News Feed, in the right column, or in Messenger. Your ad can appear in a variety of places, such as the News Feed, the Audience Network, or Instagram.

98

98

pharmaphorum

MAY 27, 2021

The approval is good news for Myovant’s partner Pfizer too, as the big pharma agreed a $4.2 The two companies share marketing rights to relugolix products in North America, while Pfizer has exclusive rights elsewhere.

FDA 98

FDA Labelling 98

PharmaShots

MARCH 29, 2023

Shots: Covant to receive $10M up front and will be eligible for ~$471M in additional milestones along with royalties on global sales The companies collaborated to develop novel small-molecule immunotherapy targeting ADAR1 for cancer patients & can be combined with other immunotherapies to enhance their efficacy Covant will be responsible for the (..)

40

40

pharmaphorum

FEBRUARY 21, 2022

It’s a key moment for the two companies, as expansion into HER2-low breast cancer has been held up as a key requirement for Enhertu (trastuzumab deruxtecan) if it is to achieve its multibillion-dollar sales expectations. billion to Daiichi Sankyo if all the ADC’s development and sales objectives are achieved.

Chemotherapy 132

Chemotherapy Labelling 132

pharmaphorum

JANUARY 29, 2021

The post-marketing safety study showed that Xeljanz (tofacitinib) – used to treat rheumatoid arthritis (RA) – was associated with a higher rate of heart attacks and cancer than a TNF inhibitor in patients aged over 50 with underlying cardiovascular risk factors. Now, a study designed to prove its safety has achieved the opposite.

Labelling 135

Labelling Patient Care FDA 135

PharmaShots

MARCH 28, 2023

is currently being evaluated in a P-III study, expected to enroll patients (n=602) at 190 clinical sites in 17 countries Ref: PR Newswire | Image: OncoVent Related News:- Macomics Signs a Worldwide Drug Discovery Collaboration Agreement with Ono to Discover and Develop Macrophage-Targeting Antibody Therapy for Cancer

40

40

pharmaphorum

DECEMBER 10, 2021

Already scrambling to refile its obeticholic acid (OCA) drug for non-alcoholic steatohepatitis (NASH) after the FDA rejected it last year, Intercept Pharma was hoping for more luck in Europe, but has now withdrawn its EU marketing application. Shares in Intercept slipped around 15% after it announced the news.

Packaging 98

Packaging FDA 98

European Pharmaceutical Review

JANUARY 24, 2023

HUTCHMED will receive $400 million upfront as well as up to $730 million on meeting regulatory, development and commercial sales milestones. This is in addition to royalties on net sales. Fruquintinib is a new oral, highly selective and potent inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, 2 and 3.

FDA 52

FDA 52

pharmaphorum

JANUARY 17, 2022

In recent years it has successfully integrated the Novartis consumer health portfolio and the Pfizer portfolio, which resulted in annual sales of £9.6 However, amid news of the proposals, GSK’s share price was up almost 5% on Monday morning, while Unilever shares fell by as much as 7.3% billion in 2021. in London.

118

118

pharmaphorum

FEBRUARY 22, 2021

AZ’s share price ticked downwards after the announcement that it will stop marketing Imfinzi, a PD-L1 class immunotherapy, for previously treated adult patients with advanced or metastatic bladder cancer. The news will come as a blow for AZ, where Imfinzi has been an important component of the company’s cancer portfolio.

FDA 52

FDA 52

PharmaShots

APRIL 3, 2023

in additional development, regulatory & commercial milestones along with royalties on net sales for both ADC assets BioNTech received exclusive licenses from DualityBio for 2 ADC assets (DB-1303 & DB-1311) directed against targets expressed in a broad range of human cancers & will obtain commercial rights globally (excl.

40

40

Pharmaceutical Technology

SEPTEMBER 2, 2022

Multiple myeloma (MM) therapeutics comprise a multi-billion dollar market, among the most valuable in oncology. Last month, the European Medicines Agency's (EMA) approval of Johnson & Johnson’s (J&J) anti-CD3/BCMA bispecific antibody Tecvayli (teclistamab) marked the fourth anti-BCMA biologic to enter the R/R MM market.

FDA 59

FDA Labelling 59

pharmaphorum

AUGUST 7, 2020

Pharma’s reputation has soared due to the COVID-19 pandemic – but coronavirus is starting to bite companies’ sales. Find out more in our roundup of the biggest R&D, market access and digital stories from the past week. Meanwhile, Bayer’s Q2 sales were down 2.5% to just over €10 billion, with pharma falling 8.8%

Nursing Homes 105

Nursing Homes Vaccines Immunization Hospitals 105

pharmaphorum

JANUARY 9, 2023

He continued: “Amryt has steadily brought innovative products to new markets and, by adding them to the Chiesi portfolio, we hope to make them available to even more patients who may require them.”. Additionally, its top-selling drug, Myalept or Myalepta, had third-quarter sales of $37.9m.

FDA 98

FDA 98

pharmaphorum

OCTOBER 28, 2022

The EMA has delivered some good news to GSK on a new long-acting HIV drug and vaccine for respiratory syncytial virus (RSV), in a week that saw multiple disappointments in other R&D projects. Nevertheless, that is a big lead for GSK to try to take on. million) for the product in the first half of this year.

Vaccines 52

Vaccines FDA 52

pharmaphorum

NOVEMBER 18, 2020

The decision means that with two CGRP antibodies now cleared for migraine prevention, the first drug in the class to be approved in Europe – Novartis’ Aimovig (erenumab) – has fallen further behind its rivals in getting access to the UK market.

96

96

pharmaphorum

DECEMBER 15, 2022

Stefan Woxström is the new senior vice president for Europe and Canada at AstraZeneca, moving over from the company’s Japanese division to take over from Iskra Reic , who will now serve as EVP of vaccines and immune therapies. New CEO in at Angelini Pharma. More CEO shakeups.

Immunization 52

Immunization Vaccines 52

pharmaphorum

NOVEMBER 18, 2020

The decision means that with two CGRP antibodies now cleared for migraine prevention, the first drug in the class to be approved in Europe – Novartis’ Aimovig (erenumab) – has fallen further behind its rivals in getting access to the UK market.

94

94

pharmaphorum

FEBRUARY 28, 2022

Amryt Pharma has been handed a major blow by the FDA, after the US regulator rejected its marketing application for Oleogel-S10, its drug for rare and debilitating skin disease epidermolysis bullosa (EB). Read Faith’s story and more personal stories at [link] & share them on your social media to help raise awareness!

FDA 98

FDA 98